Suppr超能文献

天然产物(+)-阿夫拉米维拉胺与核磷蛋白和输出蛋白-1的相互作用介导了核磷蛋白及其与急性髓性白血病相关突变体的细胞定位。

Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants.

作者信息

Mukherjee Herschel, Chan Kok-Ping, Andresen Vibeke, Hanley Mariah L, Gjertsen Bjørn Tore, Myers Andrew G

机构信息

†Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, Massachusetts 02138, United States.

‡Centre for Cancer Biomarkers, CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.

出版信息

ACS Chem Biol. 2015 Mar 20;10(3):855-63. doi: 10.1021/cb500872g. Epub 2015 Jan 5.

Abstract

Nucleophosmin (NPM1) is a multifunctional phosphoprotein localized predominantly within the nucleoli of eukaryotic cells. Mutations within its C-terminal domain are frequently observed in patients with acute myeloid leukemia (AML), are thought to play a key role in the initiation of the disease, and result in aberrant, cytoplasmic localization of the mutant protein. We have previously shown that the electrophilic antiproliferative natural product (+)-avrainvillamide (1) binds to proteins, including nucleophosmin, by S-alkylation of cysteine residues. Here, we report that avrainvillamide restores nucleolar localization of certain AML-associated mutant forms of NPM1 and provide evidence that this relocalization is mediated by interactions of avrainvillamide with mutant NPM1 and exportin-1 (Crm1). Immunofluorescence and mass spectrometric experiments employing a series of different NPM1 constructs suggest that a specific interaction between avrainvillamide and Cys275 of certain NPM1 mutants mediates the relocalization of these proteins to the nucleolus. Avrainvillamide treatment is also shown to inhibit nuclear export of Crm1 cargo proteins, including AML-associated NPM1 mutants. We also observe that avrainvillamide treatment displaces Thr199-phosphorylated NPM1 from duplicated centrosomes, leads to an accumulation of supernumerary centrosomes, and inhibits dephosphorylation of Thr199-phosphorylated NPM1 by protein phosphatase 1. Avrainvillamide is the first small molecule reported to relocalize specific cytoplasmic AML-associated NPM1 mutants to the nucleolus, providing an important demonstration of principle that small molecule induction of a wild-type NPM1 localization phenotype is feasible in certain human cancer cells.

摘要

核磷蛋白(NPM1)是一种多功能磷蛋白,主要定位于真核细胞的核仁内。急性髓系白血病(AML)患者中经常观察到其C端结构域内的突变,这些突变被认为在该疾病的起始中起关键作用,并导致突变蛋白异常定位于细胞质中。我们之前已经表明,亲电抗增殖天然产物(+)-阿维拉米德(1)通过半胱氨酸残基的S-烷基化与包括核磷蛋白在内的蛋白质结合。在此,我们报告阿维拉米德可恢复某些与AML相关的NPM1突变形式的核仁定位,并提供证据表明这种重新定位是由阿维拉米德与突变型NPM1和输出蛋白-1(Crm1)的相互作用介导的。使用一系列不同NPM1构建体的免疫荧光和质谱实验表明,阿维拉米德与某些NPM1突变体的Cys275之间的特异性相互作用介导了这些蛋白质向核仁的重新定位。阿维拉米德处理还显示可抑制Crm1货物蛋白的核输出,包括与AML相关的NPM1突变体。我们还观察到,阿维拉米德处理可使 Thr199磷酸化的NPM1从复制的中心体上移位,导致多余中心体的积累,并抑制蛋白磷酸酶1对Thr199磷酸化的NPM1的去磷酸化。阿维拉米德是首个被报道可将特定的细胞质AML相关NPM1突变体重定位至核仁的小分子,这为在某些人类癌细胞中通过小分子诱导野生型NPM1定位表型的可行性提供了重要的原理证明。

相似文献

2
Leukemia-Associated Mutations in Nucleophosmin Alter Recognition by CRM1: Molecular Basis of Aberrant Transport.
PLoS One. 2015 Jun 19;10(6):e0130610. doi: 10.1371/journal.pone.0130610. eCollection 2015.
4
The natural product avrainvillamide binds to the oncoprotein nucleophosmin.
J Am Chem Soc. 2007 Nov 21;129(46):14444-51. doi: 10.1021/ja075327f. Epub 2007 Oct 25.
5
A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.
Leukemia. 2009 Mar;23(3):501-9. doi: 10.1038/leu.2008.326. Epub 2008 Nov 13.
6
Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Cancer. 2017 May 1;123(9):1662-1673. doi: 10.1002/cncr.30515. Epub 2017 Jan 5.
7
Structural consequences of nucleophosmin mutations in acute myeloid leukemia.
J Biol Chem. 2008 Aug 22;283(34):23326-32. doi: 10.1074/jbc.M801706200. Epub 2008 May 29.
8

引用本文的文献

1
Xist condensates: perspectives for therapeutic intervention.
Genome Biol. 2025 Jul 21;26(1):215. doi: 10.1186/s13059-025-03666-8.
2
Hypoxia upregulates the expression of PD-L1 via NPM1 in breast cancer.
J Immunother Cancer. 2025 Jun 23;13(6):e010151. doi: 10.1136/jitc-2024-010151.
3
Targeting protein disorder: the next hurdle in drug discovery.
Nat Rev Drug Discov. 2025 Jun 9. doi: 10.1038/s41573-025-01220-6.
5
6
Phase separations in oncogenesis, tumor progressions and metastasis: a glance from hallmarks of cancer.
J Hematol Oncol. 2023 Dec 18;16(1):123. doi: 10.1186/s13045-023-01522-5.
7
DDX24 Mutation Alters NPM1 Phase Behavior and Disrupts Nucleolar Homeostasis in Vascular Malformations.
Int J Biol Sci. 2023 Aug 6;19(13):4123-4138. doi: 10.7150/ijbs.84097. eCollection 2023.
8
Nucleophosmin Plays a Role in Repairing DNA Damage and Is a Target for Cancer Treatment.
Cancer Res. 2023 May 15;83(10):1573-1580. doi: 10.1158/0008-5472.CAN-22-3631.
9
10
Current status and future perspectives in targeted therapy of NPM1-mutated AML.
Leukemia. 2022 Oct;36(10):2351-2367. doi: 10.1038/s41375-022-01666-2. Epub 2022 Aug 25.

本文引用的文献

1
Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.
Leuk Lymphoma. 2014 Jun;55(6):1337-44. doi: 10.3109/10428194.2013.840776. Epub 2013 Oct 9.
2
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Blood. 2013 Oct 24;122(17):3034-44. doi: 10.1182/blood-2013-04-495374. Epub 2013 Aug 22.
4
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
Leukemia. 2013 Jan;27(1):66-74. doi: 10.1038/leu.2012.219. Epub 2012 Jul 31.
5
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
Blood. 2012 Aug 30;120(9):1765-73. doi: 10.1182/blood-2012-04-423160. Epub 2012 Jun 7.
6
Natural product-inspired cascade synthesis yields modulators of centrosome integrity.
Nat Chem Biol. 2011 Dec 25;8(2):179-84. doi: 10.1038/nchembio.758.
7
Dephosphorylation of nucleophosmin by PP1β facilitates pRB binding and consequent E2F1-dependent DNA repair.
Mol Biol Cell. 2010 Dec;21(24):4409-17. doi: 10.1091/mbc.E10-03-0239. Epub 2010 Oct 20.
8
Nucleophosmin is overexpressed in thyroid tumors.
Biochem Biophys Res Commun. 2010 Jul 2;397(3):499-504. doi: 10.1016/j.bbrc.2010.05.142. Epub 2010 May 31.
9
Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.
PLoS Pathog. 2010 Mar 19;6(3):e1000818. doi: 10.1371/journal.ppat.1000818.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验